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Nanomedicine is an emerging field that integrates nanotechnology, biomolecular engineering, life sciences and medicine; it is 
expected to produce major breakthroughs in medical diagnostics and therapeutics. Due to the size-compatibility of nano-scale 
structures and devices with proteins and nucleic acids, the design, synthesis and application of nanoprobes, nanocarriers and 
nanomachines provide unprecedented opportunities for achieving a better control of biological processes, and drastic im-
provements in disease detection, therapy, and prevention. Recent advances in nanomedicine include the development of func-
tional nanoparticle based molecular imaging probes, nano-structured materials as drug/gene carriers for in vivo delivery, and 
engineered molecular machines for treating single-gene disorders. This review focuses on the development of molecular imag-
ing probes and engineered nucleases for nanomedicine, including quantum dot bioconjugates, quantum dot-fluorescent protein 
FRET probes, molecular beacons, magnetic and gold nanoparticle based imaging contrast agents, and the design and validation 
of zinc finger nucleases (ZFNs) and TAL effector nucleases (TALENs) for gene targeting. The challenges in translating nano-
medicine approaches to clinical applications are discussed.  
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Nanomedicine is an emerging field that integrates nano-
technology, biomolecular engineering, biology, and medi-
cine [1]. It focuses on the development of engineered 
nano-scale (1100 nm) materials, structures and devices for 
better diagnostics and highly specific medical intervention 
in curing disease or repairing damaged tissues. As a basis 
for nanomedicine, nanotechnology is the science, engineer-
ing, and technology related to the understanding and control 
of matter at the nano-scale, and the development of materi-
als, devices, and systems that have novel properties and 
functions due to their nano-scale dimensions or components. 
Nanotechnology also provides new abilities to measure, 
control and manipulate matter (including soft matter) at the 
nano-scale what was unthinkable with conventional tools. 
Owing to the size-compatibility of nano-scale structures 
with proteins and nucleic acids in living cells, nanomedicine 
approaches have the potential to provide unprecedented 
opportunities for achieving a better control of biological 
processes, and drastic improvements in disease detection, 
therapy, and prevention, thus revolutionizing medicine.  
Over the last ten years or so, significant efforts have been 
made in the US, China, Europe and elsewhere to develop 
nanomedicine. For example, the US National Institutes of 
Health has developed a nanomedicine centers network, and 
invested a significant amount of research funding to nano-
medicine development. Just in FY 2009 (Oct. 1, 2008Sept. 
30, 2009), the total NIH funding in nanotechnology/    
nanoscience projects was more than 410 million US dollars. 
SPECIAL TOPIC 
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Many potential applications of nanomedicine have been, or 
are being, explored, including nanoparticle-based molecular 
imaging probes for biological studies and disease detection; 
nano-carriers for targeted in vivo drug/gene delivery in more 
efficient therapy, and nuclease-based nano-devices for 
treating single-gene disorders. For basic biological studies, 
the development of new nano-scale tools and devices have 
the potential to permit imaging of cellular structures at the 
nano scale, rapid measurement of the dynamic behavior of 
protein complexes and molecular assemblies in living cells 
and animals, and a better control of intracellular machinery. 
It is expected that the multifunctional, targeted nanoparti-
cles are capable of overcoming biological barriers to deliver 
therapeutic agents preferentially to diseased cells and tis-
sues at high local concentrations, resulting in much en-
hanced efficacy and reduced toxicity. Nanomedicine ap-
proaches have the potential to allow clinicians to detect a 
disease in its earliest, most easily treatable, presymptomatic 
stage, and provide real-time assessments of therapeutic and 
surgical outcome. Nano-scale tools may also be used to 
quickly identify new disease targets for drug development 
and predict drug resistance.  
In this review, we will focus on nano-structured and na-
noparticle-based molecular imaging probes, including fluo-
rescence imaging probes and nanoparticle contrast agents 
for MRI, PET, and CT, and molecular machines using en-
gineered nucleases for gene targeting. Due to space limita-
tions, this is not intended to be a comprehensive review, but 
rather a review of selected research topics in nanomedicine 
to highlight the diversity and innovation in the field. Other 
reviews of nanomedicine can be found in recent literature 
[2,3]. Although nanomedicine has the potential to revolu-
tionize medicine, it is still in its infancy and significant 
challenges exist. Therefore, some of the major challenges 
that must be overcome are also discussed.  
1  Fluorescence imaging probes  
Fluorescence imaging probes have been widely used in bi-
ology and medicine. It is therefore not surprising that the 
development of nano-structured and nanoparticle-based 
fluorescence probes is one of the most active areas in na-
nomedicine. Described below are some of the fluorescence 
probes developed in recent years, including semi-conductor 
quantum dot (QD) based probes, and molecular beacons. 
1.1  Quantum dot bioconjugates as fluorescence imag-
ing probes  
Semi-conductor quantum dots (QDs) are core-shell nano-
crystals that have exceptionally bright fluorescence emis-
sion, with emission peaks tunable by the size of QD (typi-
cally 26 nm) (Figure 1); they have garnered much atten-
tion recently as an emerging tool for biomedical applica-
tions [423]. Since QDs were first rendered water-soluble 
[7,15], thereby making them relevant for biological studies 
in 1998, they have been applied to cell tracking studies 
[24,25], cancer imaging [13,26], flow-cytometry [27], and 
used to label membrane proteins [28,29]. The potential ap-
plications for QDs also extend to fluorescence-based detec-
tion of enzymatic activities, particularly when QDs are uti-
lized as either a donor or an acceptor for fluorescence (or 
Förster) resonance energy transfer (FRET) [3034]. QDs 
have large molar extinction coefficients (0.5×106–5×106 
M1 cm1) which makes them brighter probes under pho-
ton-limited in vivo conditions (where light intensities are 
attenuated by scattering and absorption). Since such extinc-
tion coefficients are 10–50 times larger than those of organ-
ic dyes (at 5×104–10×104 M1 cm1), QD absorption rates 
are typically 1050 times faster at the same excitation pho-
ton flux (number of incident photons per unit area). Due to 
this, individual QDs are 10–20 times brighter than typical 
organic dyes [7,10,15]. Therefore, it is possible to fluores-
cently image single individual QDs. An important aspect of 
QD labels is their extremely high photostability. QDs are 
several thousand times more stable against photobleaching 
than organic dyes, which allows real-time monitoring or 
tracking of intracellular processes over long periods of time 
(hours to days). Further, QDs have Stokes shifts (separation 
between excitation and emission peaks) as large at 300400 
nm [13]. This reduces interference from tissue autofluores-
cence in biological specimens, which often buries organic 
 
 
Figure 1  A, Quantum dots are core-shell nanocrystals. For biological studies, QDs are coated with an organic coating layer. B, Tunable light emission 
observed in semiconductor QDs. This image shows 10 distinguishable emission colors of ZnS-capped CdSe quantum dots excited with a near-UV lamp.  
From left to right (blue to red), the emission maxima are located at 443, 473, 481, 500, 518, 543, 565, 587, 610, and 655 nm. 
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dye signals. It is also possible to use multicolor QDs to 
simultaneously image several targets inside living cells or 
on the cell surface. This is especially useful in the early de-
tection and identification of cancer tumors based on multi-
ple markers [2]. 
Two key issues in utilizing QDs as fluorescent biological 
labels are (i) making high quality nanocrystals and (ii) 
choosing an appropriate surface coating technique that ena-
bles the nanocrystals to be water-soluble and functionaliza-
ble while avoiding deleterious effects on the optical proper-
ties [17,18]. To obtain robust and biocompatible QDs capa-
ble of long term stability in aqueous solution, strategies 
have been devised using direct adsorption of dihydrolipoic 
acid (DHLA) on the surface (leading to negative charges), 
and then electrostatic self-assembly to positively charged 
proteins [19,35]. Other strategies employ hydrophilic or-
ganic dendron ligands [36], and micellular encapsulation 
using phospholipids [17]. Importantly, amphiphilic polymer 
coated QDs conjugated to streptavidin have become com-
mercially available [18]. A novel approach is based on the 
adsorption of bifunctional ligands such as mercaptoacetic 
acid, mercaptosuccinic acid, dithiothreitol, glutathione or 
histidine directly to the QD surface [37]. It has been shown 
that many mercapto compounds (e.g., mercapto-benzoic/ 
propionic/undecanoic/decanoic acid) are amenable to this 
procedure [38,39]. A variation of this direct adsorption  
method is to incubate water soluble QDs with thi-
ol-containing biomolecules, which slowly replace the sur-
face mercapto ligands via mass action [4042]. However, 
all these modifications result in several macromolecules 
being attached to one nanocrystal; as a result, the overall 
size is typically 1520 nm, increased by 1215 nm above 
the original nanocrystal.   
Although QDs are very attractive fluorescence imaging 
probes for biological studies, there are challenges in using 
QD probes for intracellular imaging, including delivering 
QD probes into living cells, low signal-to-noise ratio, and 
the non-specific interaction between QDs and intracellular 
organelles. The size of QD probe, especially functionalized 
QDs may also be an issue when using QDs to study pro-
tein-protein interactions or the assembly of protein ma-
chines inside living cells due to potential interference. The 
development of QD bioconjugates of <5 nm remains a sig-
nificant challenge.  
1.2  Quantum dot-fluorescent protein FRET probes  
QDs have been used in various FRET probes [43]. QDs 
make excellent FRET donors because of their exceptional 
brightness and high quantum yields [4446], their capacity 
to bind multiple acceptor molecules [22], and the unique 
qualities of their characteristic excitation and emission 
spectra [45]. The broad excitation range of the QDs allows 
them to be excited far from the excitation range of the ac-
ceptor molecule, minimizing the background due to direct 
excitation of the acceptor, while the narrow and tunable QD 
emission peak can be optimally matched with the absorption 
spectrum of the desired acceptor. In addition, QDs with 
different sizes that emit in the visible range are best excited 
by UV light, allowing for color multiplexing [47]. Recent 
reports have described the approaches using QDs as a FRET 
donor with organic fluorophores, organic quenchers, or gold 
nanoparticles as the acceptor [3032].  
When commercially available QDs are used as donors 
for FRET studies, often the FRET acceptor is either cova-
lently bound to the organic coating using standard 
cross-linking chemistry [30] or bound using a bio-
tin-streptavidin interaction [31]. The biotin-streptavidin 
interaction is a technically simpler conjugation strategy, but 
results in large probe size and further increases the distance 
between the donor and acceptor molecules, thereby substan-
tially reducing the FRET efficiency, since the FRET effi-
ciency is inversely proportional to the distance between the 
donor and acceptor molecules to the sixth power [48]. As an 
alternative, polyhistidine peptide tags that utilize 
non-covalent, high affinity binding to metals have been de-
veloped and thoroughly characterized [22,32,49,50]. Since 
polyhistidine is able to chelate ions accessible in the ZnS 
capping layer of the most commonly used CdSe/ZnS 
core-shell QDs [50], the use of polyhistidine peptide tags in 
a QD-based FRET assay results in a much smaller distance 
between the donor and acceptor compared with other ac-
ceptor bioconjugation schemes. This strategy has been 
demonstrated for protein-QD conjugation when QDs are 
coated with dihydolipoic acid (DHLA); these QDs tend to 
aggregate under acidic conditions [51]. The polyhistidine 
peptide tag has been used with commercially-available QDs 
(QDots from Invitrogen) to demonstrate the utility of QDs 
as a bioluminescence resonance energy transfer (BRET) 
acceptor with luciferase as the donor [33]; however, in this 
case the histidine tag interacted with Ni2+ ions chelated by a 
high density of carboxyl groups in the organic coating, ra-
ther than binding directly to the inorganic QD surface. More 
recently, QD-fluorescent protein based FRET probes have 
been developed [43], based on polyhistidine coordination to 
the inorganic surface of commercially-available QDs, 
demonstrating that fluorescent proteins (FPs) are exception-
al FRET acceptors for QD donors (Figure 2). The use of 
fluorescent proteins as acceptors has several benefits. For 
example, standard molecular biology techniques can easily 
be used to modify the FPs to include the polyhistidine tag, a 
variety of linkers between the protein bulk and the tag, and 
amino acid sequences that could contribute to the function-
ality of the QD-FRET probe, such as a cleavage sequence 
for a protease in order to produce a FRET-based probe to 
measure enzyme activity. Once a plasmid for the recombi-
nant protein is designed, fluorescent proteins can be ex- 
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Figure 2  Schematic diagram of the FRET interaction between a quantum 
dot, specifically a T2-MP EviTag (Evident Technologies), and a GFP-like 
fluorescent protein. A polyhistidine sequence inserted at the N-terminus of 
the mCherry shown here coordinates to the ZnS capping layer of the QD, 
bringing the two into close proximity. Under excitation of the QD, energy 
is non-radiatively transferred to the fluorescent protein and sensitized  
emission is observed. 
pressed in E. coli in large quantities, and the presence of the 
polyhistidine on his-tagged proteins facilitates protein puri- 
fication using immobilized metal affinity chromatography 
(IMAC). The large variety of GFP-like fluorescent proteins 
now available with emission wavelengths spanning the en-
tire visible range [52,53] also provides an array of possible 
fluorescent protein acceptors for QDs with different colors. 
A specific application of the QD-FP FRET probes is the 
intracellular pH measurement in biological and disease 
studies. Intracellular pH (pHi) plays a critical role in the 
physiological and pathophysiological processes of cells [54], 
and fluorescence imaging using pH-sensitive indicators can 
provide a powerful tool to assess the pHi of intact cells and 
sub-cellular compartments. As shown in Figure 2, the 
QD-based ratiometric pH sensor, comprising a QD (as 
FRET donor) and pH-sensitive fluorescent proteins (FPs), 
exhibiting dramatically improved sensitivity and photosta-
bility compared to BCECF, the most widely used fluores-
cent dye for pH imaging. We found that Förster resonance 
energy transfer (FRET) between the QD and multiple FPs 
modulates the FP/QD emission ratio, exhibiting a >12-fold 
change between pH 6 and 8. The modularity of the probe 
enables customization to specific biological applications 
through genetic engineering of the FPs, as illustrated by the 
altered pH range of the probe through mutagenesis of the 
fluorescent protein. The QD-FP probes facilitated the visu-
alization of the acidification of endosomes in living cells 
following polyarginine-mediated uptake. These probes have 
the potential to enjoy a wide range of intracellular 
pH-dependent imaging applications that are not feasible 
with fluorescent proteins or organic fluorophores alone, 
including tracking the endosomal release of nanocarriers for 
drug/gene delivery, as well as monitoring pH and/or metal 
ion concentration in both the intracellular and extracellular 
environment. 
1.3  Molecular beacons  
The ability to image specific ribonucleic acid (RNA) in liv-
ing cells in real time can provide essential information on 
RNA synthesis, processing, transport, and localization. 
However, quantitative methods such as real-time polymer-
ase chain reaction (PCR) and DNA microarrays rely on the 
use of cell lysates thus not able to obtain important spatial 
and temporal information. Fluorescent proteins and other 
reporter systems cannot image endogenous RNA in living 
cells. Fluorescence in situ hybridization (FISH) assays re-
quire washing to achieve specificity, therefore can only be 
used with fixed cells. Nanostructured probes for RNA de-
tection in living cells have been developed; they promise to 
open new and exciting opportunities in sensitive gene de-
tection for a wide range of biological and medical applica-
tions. 
Of particular interest are molecular beacons, a class of 
ligonucleotide (ODN) hairpin probes that have been used 
for RNA imaging in living cells. As illustrated in Figure 3A, 
molecular beacons are single-stranded DNA or RNA mole-
cules labeled at one end with a reporter fluorophore and at 
the other end with a quencher; they are designed to form a 
stem-loop hairpin structure in the absence of a complemen-
tary target so that fluorescence of the fluorophore is 
quenched. Hybridization with the target nucleic acid opens 
the hairpin and physically separates the fluorophore from 
quencher, allowing a fluorescence signal to be emitted upon 
excitation (Figure 3A). This enables a molecular beacon to 
function as a sensitive probe with a high signal-to-    
background ratio. Under optimal conditions, the fluores-
cence intensity of molecular beacons can increase by >200- 
fold upon binding to their targets [55]. The ability to trans-
duce target recognition directly into a fluorescence signal 
with high signal-to-background ratio has allowed molecular 
beacons to enjoy a wide range of biological and biomedical 
applications, including real-time monitoring of PCR, geno-
typing and mutation detection, multiple analyte detection, 
assaying for nucleic acid cleavage in real-time, cancer cell 
detection, studying viral infection, and monitoring RNA 
expression and localization in living cells [5670]. 
As illustrated in Figure 3A, a conventional molecular 
beacon has four essential components, a loop, stem, fluoro-
phore, and quencher. The loop usually consists of 1525 
nucleotides and is selected to have a unique antisense tar-
geting sequence. The stem, formed by two complementary 
short-arm sequences, is typically 46 bases long and chosen 
to be independent of the target sequence. The use of a single 
type of reporter dye on each molecular beacon allows mul-
tiple, optically distinct, molecular beacons to be visualized 
simultaneously (i.e., multiplexing) [56,61]. This important 
attribute could potentially be taken advantage of to highlight 
the orchestration between various gene expression patterns 
in living cells. In fact, several groups have already demon-
strated the feasibility of simultaneously imaging multiple 
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Figure 3  Illustrations of molecular beacons for live-cell RNA detection. A, Molecular beacons are dual-labeled stem-loop oligonucleotide hairpin probes 
with a reporter fluorophore at one end and a quencher molecule at the other end. B, Dual FRET donor and acceptor molecular beacons hybridize to adjacent  
regions on the same mRNA target resulting in FRET signal. 
genes in single living cells with molecular beacons [69,70].  
To further reduce background signal, especially that due 
to degradation of beacons by endonucleases in living cells, a 
novel dual FRET-molecular beacons approach was devel-
oped; it utilizes a pair of molecular beacons each labeled 
with a donor and acceptor fluorophore as illustrated in Fig-
ure 3B [65,66]. The probe sequences are chosen such that 
the molecular beacons hybridize to adjacent regions on a 
single nucleic acid target, similar to the dual FRET-linear 
probes. The resulting FRET signal (i.e., sensitized emission 
of the acceptor fluorophore) upon probe hybridization 
serves as a positive signal, which can be readily discerned 
from non-FRET false-positive signals due to probe degrada-
tion and nonspecific probe opening. Dual FRET-molecular 
beacons, therefore, combine the low-background signal and 
high specificity of molecular beacons with the ability of 
two-probe FRET assays to differentiate between true target 
recognition and false-positive signals. It has been demon-
strated that upon hybridization to nucleic acid targets, dual 
FRET-molecular beacons can provide a better sig-
nal-to-background ratio than the single molecular beacon 
approach when appropriate FRET pairs are selected [65,66]. 
In the conventional molecular beacon design, the stem 
sequence is typically independent of the target sequence 
(Figure 3A); however, dual FRET molecular beacons can be 
designed such that all the bases of one arm of the stem (to 
which a fluorophore is conjugated) are complementary to 
the target sequence, thus participating in both stem for-
mation and target hybridization (shared-stem molecular 
beacons) [71] (Figure 3B). The advantage of this shared- 
stem design is to help fix the position of the fluorophore 
that is attached to the stem arm, limiting its degree-of- 
freedom of motion, and increasing the fluorescence reso-
nance energy transfer (FRET) in the dual FRET molecular 
beacon design.  
Dual FRET molecular beacons have been used to detect 
K-Ras, surviving and oct4 mRNAs in HDF, Miapaca-2, and 
H1 cells, respectively [66,72]. Interestingly, k-Ras mRNAs 
seemed to localize with a filamentous pattern in HDF cell 
whereas survivin mRNAs seemed to localize in a 
non-symmetrical pattern within Miapaca-2 cells, often to 
one side of the nucleus of the cell. mRNA localization in 
living cells is believed to be closely related to post-    
transcriptional regulation of gene expression but much re-
mains to be seen if such localization indeed targets a protein 
to its site of function by producing the protein ‘right on the 
spot’. Using a dual beacon approach, the transport and lo-
calization of Oskar mRNA in drosophila melanogaster oo-
cytes has also been visualized [64]. In this work, molecular 
beacons with 2′-O-methyl backbone were delivered into 
cells using microinjection and the migration of Oskar 
mRNAs were tracked in real time, from the nurse cells 
where it is produced to the posterior cortex of the oocyte 
where it is localized. Clearly, the direct visualization of 
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specific mRNAs in living cells with molecular beacons will 
provide important insight into the intracellular trafficking 
and localization of RNA molecules. 
One of the critical steps in the accurate detection of RNA 
molecules in living cells is the efficient delivery of molecu-
lar beacons into the cytoplasm. Oligonucleotide-based 
probes are generally prevented from gaining access to the 
cytoplasm due to the cell membrane [73]. Several methods 
have been developed to deliver molecular beacons into live 
cells include microinjection, electroporation, and the use of 
cell-penetrating peptides (CPP), steptolysin O (SLO) or 
polycationic molecules such as liposomes and dendrimers.  
Streptolysin O (SLO), which is a pore-forming bacterial 
toxin, has been used as a simple and rapid means of intro-
ducing oligonucleotides into eukaryotic cells [7476]. SLO 
binds to cholesterol molecules on cell surface and oli-
gomerizes them into a ring-shaped structure to form pores 
of approximately 2530 nm in diameter, allowing the influx 
of both ions and macromolecules. An essential feature of 
this technique is that the toxin-based permeabilization is 
reversible [77]. This can be achieved by introducing oligo-
nucleotides with SLO under serum-free conditions and then 
removing the mixture and adding normal media with serum 
and calcium [75,77]. Since cholesterol composition varies 
with cell types, the permeabilization protocol needs to be 
optimized for each cell type by varying temperature, incu-
bation time, cell number and SLO concentration.  
A wide variety of cargos have been delivered to living 
cells both in cell culture and in tissue using cell penetrating 
peptides [78,79]. To deliver molecular beacons into cells, 
Tat peptides were conjugated to molecular beacons using 
different linkages (Figure 4A and B); the resulting pep-
tide-linked molecular beacons were delivered into living 
cells to target GAPDH and survivin mRNAs [67]. At rela-
tively low concentrations peptide-linked molecular beacons 
were internalized into living cells within 30 min with nearly 
100% efficiency. Peptide-based delivery did not interfere 
with molecular beacon binding to survivin or GAPDH, 
since similar levels of fluorescence and a similar pattern of 
localization were seen in cells with beacons delivered using 
alternative means. Peptide-linked molecular beacons show 
impressive potential as an all-in-one molecule capable of 
self-delivery, targeting and reporting in live cells.  
Peptide-linked molecular beacons can also be delivered 
using a SLO-based approach to target RNA molecules in 
the cell nucleus by attaching a nuclear localization signal 
(NLS) peptide to a molecular beacon. Molecular beacons 
designed to target small nuclear RNAs (snRNA) U1 and U2 
were linked to NLS peptides and delivered to cells using the 
SLO based reversible membrane permeabilization method 
(Figure 4C). The small nucleolar RNA U3 was delivered 
into the nuclei of live HeLa cells, and the localization and 
co-localization (U1 and U2) of these nuclear RNAs was 
imaged [80]. This delivery method can potentially be used 
to image transcriptional and post-transcriptional processing 
of RNAs in the nucleus of living cells.  
2  Nanoparticle-based MRI and MR/PET im-
aging contrast agents 
Multimodality imaging combines two or more distinct im-  
 
 
Figure 4  A schematic of peptide-linked molecular beacons. A, A peptide-linked molecular beacon using the thiol-maleimide linkage in which the quench-
er-arm of the molecular beacon stem is modified by adding a thiol group which can react with a maleimide group placed to the C terminus of the peptide to 
form a direct, stable linkage. B, A peptide-linked molecular beacon with a cleavable disulfide bridge in which the peptide is modified by adding a cysteine 
residue at the C terminus which forms a disulfide bridge with the thiol-modified molecular beacon. This disulfide bridge design allows the peptide to be 
cleaved from the molecular beacon by the reducing environment of the cytoplasm. C, A schematic illustration of the design of a peptide-linked molecular 
beacon and its delivery into cell nucleus. The NLS peptide is covalently linked to the molecular beacon using a modified nucleotide in its quencher arm. The 
NLS linked molecular beacons are delivered into the cytoplasm first using Streptolysin O (SLO), and the NLS peptide actively transports the probes into the  
nucleus of a living cell. 
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aging modalities in a way that leverages the respective 
strengths and weaknesses of each imaging technology. Ex-
amples include combined PET-CT [81], PET-MR [82,83] 
and MR-fluorescence imaging [84,85], which often gener-
ates results superior to both modalities operating separately. 
The combination of positron emission tomography (PET) 
with X-ray computed tomography (CT) has become the 
gold standard in oncologic imaging [81]. Positron emission 
tomography is the most sensitive human molecular imaging 
modality and produces whole body images of functional and 
molecular information. CT rapidly acquires whole-body 
images at high resolution but exposes patients and experi-
mental animals to substantial doses of ionizing radiation. 
Magnetic resonance imaging (MRI), in comparison, uses no 
ionizing radiation and provides soft tissue contrast superior 
to CT. Combining PET with the high-resolution, spectro-
scopic, or contrast enhancement abilities of MRI would 
produce a breakthrough in the detection and monitoring of 
disease [82]. 
Nanoparticles possess unique characteristics that make 
them well suited as probes for molecular imaging [86]. Na-
noparticles, including metal, metal oxide and semi-    
conductor nanoparticles can be synthesized in a systematic 
fashion to have precise diameter with narrow size distribu-
tions. As particles become smaller, their surface area to 
volume ratio increases significantly. Engineering of nano-
particle surface chemistry allows the surface area to be dec-
orated with therapeutic molecules, imaging agents, targeting 
ligands, or nucleic acids. To perform nanoparticle-based in 
vivo imaging of molecular markers associated with disease 
development, the nanoparticles must be functionalized with 
specific targeting ligands [87]. Distinct ligands and report-
ers can be attached to a single particle to allow multiplexing 
and multi-functionality. A single nanoparticle can be con-
jugated with a large number of targeting ligands, increasing 
the affinity of the nanoparticle to its biological target 
through a phenomenon known as multivalency. Additional-
ly, a nanoparticle can be conjugated with a large number of 
reporter molecules (e.g., fluorophores, radionuclides), in-
creasing signal-to-noise in imaging applications.  
The unique qualities of nanoparticles described above 
make them superior in many ways to traditional low molec-
ular weight MRI contrast agents and PET probes [88]. 
Compared to gadolinium-based MRI contrast agents, nano-
particle MRI contrast agents circulate in the blood for long-
er periods of time, offer greater sensitivity, and may pro-
duce fewer side-effects [89]. Radiolabeled nanoparticles can 
circulate for longer periods of time than small molecule 
PET tracers and can carry greater numbers of radionuclides 
[90]. Nanoparticles are therefore a promising platform for 
the construction of MRI and PET contrast agent for in vivo 
imaging. 
The most promising nanoparticle system as contrast 
agent for multimodality in vivo imaging is superparamag-
netic iron oxide nanoparticles (SPIOs) [91,92]. A variety of 
SPIOs with different cores and surface coating were synthe-
sized, and several are currently under clinical trials for im-
aging liver tumors and metastatic lymph nodes [9398]. A 
SPIO, in general, is composed of maghemite or magnetite 
crystals less than 20 nm in diameter. Unlike widely used 
paramagnetic gadolinium chelates, these nanocrystals con-
tain thousands of Fe atoms and approach saturation mag-
netization under a magnetic field typical for MRI [99]. Each 
nanocrystal can generate signal contrast several orders of 
magnitude higher than a gadolinium chelate. In addition, 
iron oxide has little toxicity for in vivo applications. These 
features make SPIOs an appealing candidate for early de-
tection and diagnosis of human diseases [96,100102]. 
A novel nanoparticle-based dual-modality PET/MR im-
aging contrast agent consists of a SPIO core coated with 
PEGylated phospholipids and labeled with a radiotracer 
(64Cu) [103], as shown in Figure 5A. To label SPIOs with 
positron-emitting 64Cu, the chelator 1,4,7,10-tetraazacy- 
clo-dodecane-1,4,7,10-tetraacetic acid (DOTA) was conju-
gated to PEG termini. The 64Cu-SPIO probes produced 
strong MR and PET signals, and were stable in mouse se-
rum for 24 h at 37°C. Biodistribution and in vivo PET/CT 
imaging studies of the probes showed a circulation half-life 
of 143 min, and high initial blood retention with moderate 
liver uptake, making them an attractive contrast agent for 
disease studies.  
For an imaging modality with specific design character-
istics, the performance of in vivo imaging is determined by 
signal-to-noise ratio and detection sensitivity; nanoparti-
cle-based contrast agent can improve both. It is critical to 
synthesize SPIOs with substantial signal enhancement on a 
per-particle basis to improve sensitivity, and to tailor nano-
particle surface chemistry to optimize the specific accumu-
lation (attachment) of SIPOs in diseased cells, tissues or 
organs. There are two major factors in determining the sig-
nal enhancement generated by the SPIOs: iron oxide core 
(size and material) and the coating (thickness and chemical 
composition). SPIOs can induce an increased T2 relaxivity 
in MRI, which is determined by the translational diffusion 
of water molecules in the inhomogeneous magnetic field 
surrounding the SPIO [104106]. It has been established 
that T2 relaxivity of SPIOs increases with the magnetization 
and the size of iron oxide cores if the total amount of iron is 
constant [104,107]. The magnetization of SPIOs can be en-
hanced by using cores formed by elementary iron or by 
doping iron oxide with other magnetic elements such as 
nickel, cobalt and manganese [96,108,109]. Further, the 
core size of SPIOs can be increased by employing control-
lable crystallization through thermo-decomposition of iron 
complex in organic solvents [94,95,109,110]. 
To date, many nanocrystals are initially prepared as a 
colloid stabilized by hydrophobic surfactants in nonpolar 
solvents. For example, iron oxide nanoparticles and quan-
tum dots can be synthesized by thermal decomposition of 
precursor compounds in organic solvents [94,111,112]. 
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These methods facilitate size tuning and improve the size 
distribution of nanocrystals. However, as-synthesized na-
noparticles will aggregate in aqueous buffers unless pro-
tected by hydrophilic molecules. In order to disperse in 
aqueous solutions and be functionalized, the iron oxide core 
needs to be coated with either natural macromolecules or 
synthetic polymers [94,98,113]. Although the physical 
functionality of a nanoparticle is mainly attributable to its 
crystalline core, the coating plays an indispensible role in 
the biomedical applications. The coating layer must render 
nanoparticles water-dispersible, prevent aggregation, reduce 
non-specific adsorption in biological systems, and provide a 
platform for conjugation of targeting ligands or other func-
tionalities. The size, charge, hydrophilicity and flexibility of 
the coating molecules are critical mediators for the in vitro 
and in vivo performance of nanoparticles [109,114,115]. For 
example, the coating molecules of a SPIO can exclude wa-
ter from its surface, hinder water diffusion, or immobilize 
nearby water molecules by forming hydrogen bonds, all 
may affect the nuclear relaxation of water protons. SPIOs 
synthesized with distinct coating schemes can exhibit sig-
nificantly different T2 relaxivity even if their iron oxide core 
sizes are similar. Furthermore, the density and class of reac-
tive groups on the nanoparticle surface are not only im-
portant for conjugation chemistry but also regulate the in-
teractions between nanoparticles and their targets 
[116118]. 
Amphiphilic surfactants can be adsorbed to the surface of 
hydrophobic nanoparticles with the hydrophilic portion of 
the surfactants exposed to the aqueous solution. The adsorp-
tion is driven by hydrophobic interactions between the am-
phiphilic surfactants and the nanoparticle surface. Am-
phiphilic polymers with a low critical micelle concentration 
(CMC), e.g., Poloxamer®, Poloxamine® and lipid-PEG co-
polymer, can form a stable coating layer around hydropho-
bic cores [98,114,119]. Amphiphilic polymer coated carbon 
nanotubes, polystyrene beads, quantum dots, and super-
paramagnetic iron oxide nanoparticles have been used in in 
vitro and in vivo applications [17,97,98,114,120,121]. This 
coating can be generalized for many hydrophobic nano-
crystals because it does not rely on the reactivity of the 
crystal surface [98]. This method can also be used to pro-
duce multifunctional nanoparticles by adding functionalized 
polymers to the initial coating mixture, making it an attrac-
tive approach for coating nanocrystals with hydrophobic 
surfaces [122]. 
Hydrophobic nanocrystals are usually encapsulated with 
amphiphilic polymers through a film hydration process 
[17,97,122,123]. In this method, amphiphilic polymers and 
nanocrystals are first distributed in a thin film, which is of-
ten performed by dispersing all components in chloroform 
and evaporating the solvent with a rotary evaporator, re-
sulting in a film with uniformly distributed components. 
The components can assemble into water-dispersible nano-
particles when the film is hydrated in an aqueous buffer.  
This process usually requires energy input from intensive 
heating and sonication. The coating formation depends on 
the polymer concentration, ionic strength, pH value and 
temperature [124,125]. Despite its broad usage, the film 
hydration procedure is hindered by two competing process-
es: formation of empty micelles by the coating polymers 
alone and aggregation of nanocrystals. The aggregation of 
nanocrystals is nearly irreversible due to their high surface 
energy. To avoid aggregation, it is crucial to separate the 
individual nanocrystals with the coating polymers in the 
thin film. A common approach is to increase the ratio be-
tween the coating polymers and nanocrystals in the initial 
mixture. However, it is difficult to achieve a good separa-
tion of nanocrystals using the film hydration method, and 
the coated nanoparticles are often accompanied by a large 
amount of empty micelles and aggregated nanocrystals. In 
addition, certain functional groups, e.g., maleimide, can 
hydrolyze readily in aqueous buffers once heated, thus in-
compatible with the film hydration method.  
Recently, a dual solvent exchange method was developed 
for forming water-dispersible nanoparticles with a small 
amount of amphiphilic polymers [126]. In this method, the 
abrupt phase transition (from a solid film to a solution) in 
film hydration is replaced with a mild solvent exchange 
procedure performed entirely in solution. Specifically, 
DMSO, which is miscible with chloroform and water, is 
used to bridge the gap between the two solvents. Compared 
with the conventional film hydration method, this new 
method requires less work on purification, leads to much 
improved coating efficiency and quality, and can be readily 
adopted for large-scale coating of a broad range of nano-
crystals. This method also provides a means to control the 
density of coating molecules and reactive groups on the 
nanoparticle surface. In particular, the amount of initial 
amphiphilic polymer required for effective nanoparticle 
coating is one to two orders of magnitude lower than those 
reported in the literature, which minimizes the formation of 
empty micelles. The dual solvent exchange method facili-
tates a uniform and controllable surface modification of 
nanoparticles with variable surface density of DSPE-PEG 
and functional groups, which may reduce non-specific in-
teraction with proteins, achieve desirable in vivo biodistri-
bution of nanoparticles, and significantly enhance the ability 
of nanoparticles to target specific disease markers. 
To demonstrate the ability of detecting early-stage tumor 
using SPIOs as a contrast agent in MRI, animal studies of in 
vivo tumor imaging were performed with DSPE-PEG coat-
ed SPIOs [115], which exhibited longer blood circulation 
half-life (23.2 min) compared with other nanoparticles 
coated with DSPE-mPEG1000. Tumors were induced by 
implanting human U87 glioblastoma cells subcutaneously in 
nude mice. After the tumors reached 35 mm in diameter, 
the tumor-bearing mice were examined with a 7T MRI 
scanner before and one hour after tail vein injection of SPI-
 Tong S, et al.   Sci China Life Sci   October (2012) Vol.55 No.10 851 
Os conjugated with antibodies against mouse VEGF recep-
tor-1. The specificity of VEGFR-1-targeting SPIOs was 
confirmed using an in vitro assay. As shown in Figure 6, 
injection of the 14 nm SPIOs resulted in a significant en-
hancement in T2 contrast of the tumor tissue.  
Although nanoparticle-based contrast agents for MRI or 
combined MR/PET imaging have a great potential, there are 
also significant challenges in translating the nanotechnology 
into clinical use. Clearly, the nanoparticle probes must have 
good biocompatibility and minimal toxicity [127]. The 
clearance of nanoparticles from the body, if they are not 
biodegradable, is a very important aspect. It is also essential 
to have a sufficient accumulation of nanoparticles inside (or 
on the surface) of diseased cells, tissues (such as tumor) or 
organs in order to generate a high enough signal-to-noise 
ratio in disease detection. Achieving a good balance among 
sensitivity, signal-to-noise ratio and safety, the size, func-
tionalization (the type and amount of targeting ligand), sur-
face chemistry (coating, reporters) and the total amount of 
contrast agent delivered need to be optimized.  
3  Nanoparticle-based CT contrast agents 
X-ray computed tomography (CT) is one of the most widely 
used imaging modalities in diagnostic medicine due to the 
cost effectiveness, deep tissue penetration, and high resolu-
tion [128]. CT contrast agents are typically iodine or barium 
compounds, which are usually used for intravascular and 
gastro-intestina imaging, respectively. Currently, small io-
dinated molecules are routinely used for in vivo contrast 
enhancement in the clinical setting, since iodine has a high 
X-ray absorption coefficient among nonmetal atoms. How-
ever, short circulation half-life, non-specific distribution, 
and potential renal toxicity have limited their imaging and 
targeting performance in vivo [129]. Liposomes with en-
trapped iodinated molecules are effective contrast agents 
due to their prolonged circulation half-time [130]. In one 
study, nodules showed significantly higher signal enhance-
ment even on day 3 and day 7 after tail vein injection of 
liposomal-Iodinated contrast agent [131]. There have also 
been studies focusing on iopromide-containing lipid vesi-  
 
 
Figure 5  Nanoparticle-based contrast agents in vivo imaging and drug/gene carriers for in vivo delivery. A, Iron oxide magnetic nanoparticle probes for 
MRI and combined MR/PET medical imaging. B, Nanocarriers for targeted drug/gene delivery in disease treatment. 
 
Figure 6  SPIO based in vivo tumor imaging. MRI experiments were performed using spin-echo sequence. A, Arrow shows the location of the subcutane-
ous tumor. B and C, MR images of tumor before probe injection. D and E, MR images collected after 1 h following the injection of 14 nm SPIOs conjugated  
with antibodies against mouse VEGFR-1. Red dotted lines in B and D outline the tumor. Scale bar, 5 mm. 
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cles for CT imaging of liver tumor, which has progressed to 
the clinical trials [132]. However, It is necessary to have a 
very high total iodine dose to achieve significant contrast 
enhancement, and the associated high lipid concentrations 
raise a significant concern of the toxicity and clearance of 
liposomal CT contrast agent. 
Over the past decade or so, nanoparticle based CT con-
trast agents that comprise high atomic number (high-Z) 
metal elements (such as gold, silver, bismuth, and tantalum) 
have emerged to overcome the shortcomings of iodine 
agents. Clearly, an optimal nanoparticle CT contrast agent 
should have high X-ray attenuation coefficient, low toxicity 
and cost, and small size. Since gold has a higher atomic 
number and X-ray absorption coefficient than iodine, gold 
nanoparticles (GNPs) have been developed as a CT contrast 
agent in recent years. Measurement of the X-ray absorption 
coefficient in vitro revealed that the attenuation of polyeth-
ylene glycol (PEG) coated GNPs (30 nm in diameter) is 5.7 
times higher than that of the current iodine-based CT con-
trast agent. These GNPs also had a much longer blood cir-
culation half-life than clinically used CT contrast agent (<10 
min) [133]. Dendrimer-entrapped gold nanoparticles (Au 
DENPs) have also been developed as a molecular probe for 
CT imaging. Compared with traditional iohexol, the vascu-
lar system and the urinary system could be clearly imaged 
after 20 and 60 min injection respectively of Au DENPs 
into the tail vein [134].  
Owing to the fact that silver nanoparticles (Ag NPs) have 
structural and crystalline similarity to gold nanoparticles, 
Ag NPs with tunable sizes can also be used for CT imaging. 
Dendrimer-stabilized silver nanoparticles (Ag DSNPs) with 
a diameter of 16.1 nm displayed an X-ray attenuation inten-
sity close to that of a clinically used iodine-based contrast 
agent (Omnipaque) at the same molar concentration of the 
active element (Ag versus iodine), although the atomic 
number of Ag is lower than that of iodine, suggesting that 
Ag DSNPs have a great potential to be used as a CT imag-
ing contrast agent [135]. 
Ever since noble metal nanoparticles were developed as 
X-ray contrast agents, researchers have been actively seek-
ing alternative nanoparticle-based imaging probes that are 
not expensive for clinical use. Polymer-coated Bi2S3 nano-
particles were recently reported as an injectable CT contrast 
agent for enhanced in vivo imaging of the vasculature, liver 
and lymph nodes in mice [136]. With more than a five-fold 
increase in X-ray absorption than iodine, long circulation 
half-life in vivo, and an efficacy/safety profile comparable 
to or better than iodinated contrast agents, these nanoparti-
cles and their bioconjugates may potentially be used for 
clinical CT imaging [137] (Figure 7). Targeted peptide 
(LyP-1) conjugated on the surface of Bi2S3 nanoparticles 
increased the homing efficacy of nanoparticles to breast 
tumor [138], suggesting that Bi2S3 nanoparticles can be de-
veloped as a targeting contrast agent for CT molecular im-
aging. 
Tantalum is another strong candidate as a CT contrast 
agent due to its high X-ray attenuation coefficient, bioinert-
ness and low cost. Tantalum oxide (TaOx) nanoparticles 
 
 
Figure 7  Bi2S3 nanoparticles as CT contrast agent. A, TEM image of Bi2S3 nanoparticles. B, CT value (HU) of PVP-coated Bi2S3 nanoparticles/Iobitridol 
as function of the concentration. C, Cell uptake analysis: bright field images (top) and CT images (bottom) of HeLa cells incubated with PVP-coated Bi2S3 
nanoparticles and Iobitridol and without contrast agent for 24 h. D, In vitro CT images of PVP-coated Bi2S3 nanoparticles and Iobitridol with different con- 
centrations. E and F, In vivo X-ray CT imaging of PVP-coated Bi2S3 nanoparticles. G and H, In vivo X-ray CT imaging of Iobitridol [137]. 
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exhibited remarkable performances in in vivo X-ray CT 
angiography and bimodal image-guided lymph node map-
ping [139]. Most importantly, TaOx nanoparticles can be 
easily functionalized with various biomolecules for tis-
sue-specific uptake and multimodal imaging applications 
[140]. 
4  Nanoparticles for combined imaging and 
therapy 
In cancer chemotherapies and gene therapies, the success of 
treatment relies on efficient delivery of therapeutics to the 
tumor. Although passive and active targeting can be ex-
plored to improve the efficacy of drug delivery, it is well 
recognized that solid tumors are highly heterogeneous in 
terms of vessel density, vascular permeability and intersti-
tial compositions [141]. Drug distribution in the tumor may 
change considerably with the tumor type, stage and location. 
It is therefore critical to optimize drug/gene treatment for 
individual patients. The field of image guided drug delivery 
addresses this issue by utilizing imaging methods to monitor, 
guide and evaluate targeted delivery of therapeutics to tu-
mor tissues. To avoid variations in the pharmacokinetics of 
imaging contrast agents and drug delivery vehicles, it is 
desirable to combine imaging and therapeutic functions to 
the same agent, which is often referred to as a theranostic 
agent. 
With only a few exceptions, theranostic agents are de-
veloped using nanoparticle platforms. Over the past decade 
or so, nanoparticles with unique optical, magnetic and 
plasmonic properties have been extensively studied as con-
trast agents for different imaging modalities. Recent ad-
vances in nanofabrication further provide nanoparticles with 
rich physical and chemical properties that facilitate the in-
corporation of small molecular moieties. Multiple function-
alities can be readily integrated to the same nanoparticle by 
modulating its structural and/or chemical compositions. A 
typical theranostic nanoparticle may have part or all of the 
following components: (i) imaging contrast agents, (ii) 
chemical bonds or physical interactions for loading and re-
leasing of drugs and genes, (iii) targeting ligands, and (iv) 
elements that respond to external triggers such as ultrasound, 
light and magnetic field. Summarized in Table 1 are some 
of the functionalities that have been integrated using 
theranostic nanoparticles. While numerous combinations of 
these functionalities have been achieved, due to space limi-
tations, only a few examples are covered in this review. 
Imaging guided drug delivery can be performed by com-
bining nanoparticles with distinct functions. For example, 
tumor targeting, imaging and drug delivery were performed 
with sequentially administrated gold nanorods, iron oxide 
nanoworms and drug loaded liposomes [142]. Gold nano-
rods bound to tumor vessels converted electromagnetic en-
ergy into heat, which triggered a blood coagulation cascades. 
This in turn led to enhanced accumulation of magnetic iron 
oxide nanoparticles or drug loaded liposomes that target 
fabrin and the coagulation transglutaminase FXIII. As the 
same time, thermographic imaging and fluorescence imag-
ing were applied to examine the heating of gold nanorods 
and the tumor accumulation of iron oxide nanoparticles. 
Magnetic iron oxide nanoparticles are the most well 
studied theranostic nanoparticles owing to their excellent 
biocompatibility [143], superior MRI T2 contrast [115], 
magneto-mobility [144] and capability to be heated with an 
alternating magnetic field (Figure 5B) [145]. In the past few 
years, many forms of iron oxide nanoparticle based drug 
carriers have been developed by encapsulating iron oxide 
nanocrystals with various surface coating. It has been 
shown that mitoxantrone conjugated to starch coated SPIOs 
could effectively treat VX-2 squamous cell carcinoma in a 
rabbit model [146]. In this study, the SPIOs administrated 
intra-arterially were retained at the tumor site by an elec-
tromagnet, thus significantly reducing systemic toxicity. 
However, drug loading via chemical conjugation is restrict-
ed to a small group of drug molecules with reactive moieties. 
In contrast, iron oxide nanocrystals with micellar coating 
have great promise as carriers for many small chemothera-
peutic drug molecules [147150]. In micellar nanoparticles, 
iron oxide nanocrystals are synthesized with nonpolar cap-
ping molecules. Water-dispersible nanoparticles are ob-
tained by coating the nanocrystals with a monolayer of am-
phiphilic copolymers through hydrophobic interactions 
[119,126]. Small hydrophobic molecules such as doxorubi-
cin and paclitaxel can be stored in the hydrophobic core of 
micellar nanoparticles. The nanoparticles with amphiphilic 
capping molecules covalently bound to iron oxide surface 
can also adsorb drug molecules by hydrophobic interactions 
[151,152]. Another coating with broad drug loading capa-
bility is mesoporous silica [153]. Mesoporous silica coated 
magnetite exhibits excellent T2 relaxivity and tumor imag-
ing potentials. Small drug molecules and fluorophores can 
be loaded into the porous silica shell through either chemi-
cal conjugation or electrostatic interactions. Drug loading 
by hydrophobic or electrostatic interactions often affords 
much higher loading capacity than that of chemical conju-
gation. Nevertheless, drug molecules may be prematurely 
released from the nanoparticles in systemic circulation. To 
what extent the MRI signal of nanoparticles can predict the 
bio-distribution of drug molecules requires careful exami-
nation. Other major types of magnetic delivery vehicles 
include liposomes or cerasomes containing iron oxide 
nanocrystals. Magnetic liposomes containing doxorubicin 
accumulated in tumors under the influence of a magnetic 
field and significantly suppressed tumor growth [154]. 
Magnetic iron oxide nanoparticles have also been used as 
the carriers for in vivo gene delivery. The iron oxide cores 
provide MRI signal contrast and magneto-mobility. Multi-
functional nanoparticles were constructed by simultaneous-
ly conjugating siRNA, near infrared fluorophores (Cy5.5) 
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Table 1  Functionalities of theranostic nanoparticles 
Imaging modalities Drug/gene loading mechanisms Other functionalities 
MRI (SPIOs, MnO, Gd3+) 
[147153,155157,160162] 
CT (gold nanoparticles, iohexol liposomes) [163] 
Fluorescence imaging (quantum dots, upconver-
sion nanocrystals and organic fluorophores) 
[147,152,153,164,165] 
PET (64Cu) [159] 
SPECT (111In, 99mTc, 123I and 131I) 
Thermoaccoustic imaging 
(gold nanorods and gold nanocages) 
Chemical conjugation [155,156,160,166] 
Encapsulation (liposomes) [154] 
Hydrophobic interaction (micelles and nanoparticles 
coated with amphiphilic polymers) [147150] 
Electrostatic interaction (positively charged liposomes, 
polymers and mesoporous silica) [144,159] 
 
Degradability (pH sensitive, enzyme 
cleavable, and reducible bonds) [160,166] 
Heat generation (infrared laser, alternat-
ing magnetic field and ultrasound) 
[145,165] 
Magneto-mobility 




and cell membrane translocation peptides to dextran coated 
iron oxide nanoparticles [155]. Tumor accumulation of the 
nanoparticles was confirmed with both MRI T2 imaging and 
fluorescence imaging and was in good agreement with the 
knockdown effects of siRNAs. In a similar preparation, 
siRNA, Cy5 and RGD peptides were conjugated to the sur-
face of MnFe2O4 nanoparticles that possess high T2 relaxiv-
ity [156]. Magnetic liposomes that bound siRNAs by elec-
trostatic interactions were also developed, which inhibited 
tumor angiogenesis and proliferation by suppressing the 
expression of EGF receptor in a mouse tumor model [144]. 
Iron oxide nanoparticles can only provide dark contrast 
in MRI, which is difficult for quantitative determination of 
the nanoparticle concentration. In contrast, nanoparticles 
conjugated with Mn2+ or Gd3+ chelates are capable of gen-
erating a bright signal in T1-weighted MRI images. Such 
nanoparticles include micelles, polymeric particles and lip-
osomes. However, most T1 contrast agents have poor relax-
ivity compared with the T2 relaxivity of iron oxide nanopar-
ticles. Recently, hollow MnO nanoparticles were developed 
as a dual T1 and T2 contrast agent [157]. Core-shell T1-T2 
dual mode nanoparticles that combined both MnFe2O4 and 
gadolinium were also synthesized [158]. It was showed that 
by separating gadolinium and MnFe2O4 with a silica oxide 
layer, the nanoparticles achieved both high T1 and T2 relax-
ivity. Performing both T1- and T2-weighted imaging could 
help exclude faulty signals and enhance diagnostic accura-
cy. 
PET and SPECT (single-photon emission computed to-
mography) are being actively investigated for tumor detec-
tion. Both imaging techniques have excellent detection sen-
sitivity but offer no anatomical information. The two imag-
ing techniques are often combined with CT or MRI in order 
to locate the site of the signal. PET and SPECT utilize radi-
oisotopes such as 64Cu, 111In and 99mTc, the chelates of 
which can be conjugated to nanoparticles similar to that of 
Gd3+. For example, 64Cu-DOTA was linked to siRNA, 
which is in turn conjugated to transferrin targeted poly-
cation nanoparticles for combined cancer imaging and 
treatment [159]. The bio-distribution of the nanoparticles 
was readily obtained in overlaid CT/PET images.  
5  Engineered molecular machines for disease 
treatment 
One of the most important areas of nanomedicine is the de-
velopment of novel engineered molecular machines that 
possess the ability to quantify, control and manipulate bio-
logical functions in living cells in order to treat or prevent 
diseases. At the nanometer scale, these molecular machines 
are typically multi-component and multi-functional, with 
target recognition, actuation, manipulation, self-assembly 
and disassembly functions. Compared with simpler 
nano-scale devices, such as nanoparticle-based targeted 
drug/gene delivery vehicles and imaging contrast agents, 
molecular machines perform highly specific manipulation 
(such as DNA cutting) of biomolecular complexes in/on a 
living cell, therefore have much more demanding design 
requirements.  
To date, the most promising molecular machines for na-
nomedicine applications are custom designed nucleases, 
which have become a valuable tool for specifically cleaving 
genomic sequences [169]. As shown in Figure 8, the pri-
mary forms of targetable nucleases are zinc finger nucleases 
(ZFNs) and transcription activator-like effector nucleases 
(TALENs) [170,171], each consists a DNA binding domain 
(zinc finger or Tal effector) fused to the Fok I non-specific 
DNA cleavage domain. These nucleases can be designed to 
create a DNA double-strand break (DSB) in a specific 
(pre-determined) target sequence, which can be repaired by 
the cellular DNA repair machinery. The primary means of 
re-ligation is error-prone non-homologous end joining 
(NHEJ). If a donor DNA template is supplied along with the 
nucleases, the break can be repaired using the homologous 
recombination (HR) pathway. This process can lead to ge-
nome editing of the endogenous gene if the donor sequence 
is mutated, has deletions, or contains additional sequences. 
Alternatively, HR trigger by ZFN or TALEN induced DSB 
can correct mutations of a gene that cause disease. Nucle-
ase-induced DSB near the mutation can greatly increases 
the rate of HR [172], incorporating the supplied donor tem-
plate, thereby enabling isolation of modified genes. The 
high efficiency of genome editing has greatly enhanced the 
capability to edit genomic sequences for basic research as 
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Figure 8  Engineered nucleases for gene targeting. Zinc finger nucleases (ZFNs) formed by coupling zinc finger proteins to Fok I nuclease domains can 
bind to a targeted DNA sequence and cut the DNA. Each zinc finger binds to 3 DNA bases, so a pair of 3-finger ZFNs can recognize an 18 bp DNA se-
quence. A transcription activator-like effector nuclease (TALEN) is formed by biding the Fok I nuclease domain to a transcription activator-like effector 
(TALE) consisting of an array of tandem repeats that mediate DNA recognition. Each repeat sequence contains a RVD (repeat variable di-residue) that de- 
termines base preference. A pair of nucleases (ZFNs or TALENs) are required to generate a double strand break or a nick on the DNA. 
well as medical applications. 
The specificity of ZFNs and TALENs is greatly in-
creased by the need for a pair of nucleases, each binds one 
of the two target half-sites with correct orientation and 
spacing, resulting in Fok I dimerization and cleavage of the 
intervening DNA [173,174] (Figure 8). The DNA binding 
domains can either be Zinc Finger Proteins for ZFNs or 
transcription activator-like effector domains for TALENs. 
ZFNs have been in use for years and have been used exten-
sively to modify the genomes of multiple model organisms 
and human cells. Their use has been limited by the difficul-
ty in their rational design, which is greatly hindered by the 
importance of context on binding specificity. TALEN de-
sign is greatly simplified due to the straightforward rela-
tionship between the proteins sequence and binding speci-
ficity. The specificity of TALEN comes from a pair of 
amino acids within the ~34 amino acid repeats, the ‘re-
peat-variable di-residues’ (RVDs) [170,175]. 
The successful application of custom designed, engi-
neered nucleases for treating human diseases requires iden-
tification of the possible off-target cleavage evens. The 
cleavage of nucleases at sites besides their target site is 
commonly referred to as off-target sites, and can lead to 
mutations, deletions or chromosomal changes. At this point 
there have been limited studies on off-target cleavage, but 
both ZFNs and TALENs have been found to have off-target 
cleavage, as identified by detecting NHEJ directed 
mis-repair at putative sites identified through similarity to 
the target sequence [176], or through methods monitoring 
DNA breaks or cytotoxicity. 
Several methods have been introduced to improve the 
specificity of pairs of custom nucleases. The first is the 
modification of the Fok I domains to require that dimeriza-
tion is only accomplished with one “left” and one “right” 
nuclease [177]. Another method uses a mutation that ren-
ders one of the two nucleases catalytically inactive, result-
ing in a single stranded break, though with decreased activ-
ity [178]. 
There are many potential medical applications of engi-
neered nucleases, including the establishment of HIV-1 re-
sistance in CD4+ T cells by genome editing [179], and cor-
recting genetic defects (including mutations, deletions or 
insertions) in treating single-gene disorders. An example is 
ZFN/TALEN based treatment of sickle cell disease (SCD) 
that caused by a single (A-T) mutation in the beta-globin 
gene. SCD is a painful and life shortening disease and af-
flicts primarily persons of African origin [180]. To use en-
gineered nuclease to treat SCD, it will be necessary to de-
sign and optimize ZFNs or TALENs that bind specifically 
to the beta-globin gene, deliver them as well as wild-type 
donor templates into the nuclei of hematopoietic stem and 
progenitor cells (HSPCs) to induce a DSB or a nick at a 
preselected site near the beta-globin locus, shepherding the 
broken DNA ends into the homologous recombination (HR) 
pathway for gene correction. The autologous gene-corrected 
HSPCs can then be re-engrafted in the SCD patient to pro-
duce healthy red blood cells and replace sickle cells. HSPCs 
are the normal precursors of all blood cells, including the 
oxygen-carrying erythrocytes rendered dysfunctional in 
sickle cell patients. These cells are relatively rare in the 
body, but possess potent regenerative potential in that trans-
plantation of a small amount of HSPCs is sufficient to re-
build the entire blood system of an organism. Thus, by iso-
lating HSPCs that carry the sickle mutation, correcting this 
mutation ex vivo, and then transplanting the gene-corrected 
HSPCs back into affected recipients, it will be possible to 
provide enduring replacement of the blood-producing cells 
of SCD patients with unaffected precursors, thereby sup-
plying healthy red blood cells and effectively curing the 
disease.  
Although the gene correction approach for treating SCD 
rests on established scientific principles without any con-
856 Tong S, et al.   Sci China Life Sci   October (2012) Vol.55 No.10 
ceptual barrier to its implementation, there are many practi-
cal and technological challenges in translating the nucle-
ase-based gene correction approach to clinical practice. 
These include shifting repair pathway choice from NHEJ 
toward HR, increasing the spontaneous rate of gene correc-
tion by many orders of magnitude, identifying and mini-
mizing unwanted off-targeting effects and gene rearrange-
ments, and establishing a high-throughput, high efficiency 
delivery capability. These challenges can be overcome by 
optimizing nuclease and donor template designs, exploring 
alternative delivery methods, and applying novel imaging 
probes and methods to observe and systematically optimize 
each step in the gene correction process. It is likely that the 
methods and technologies developed in nuclease based SCD 
treatment can be applied to treating other diseases. It has 
been estimated that there are ~10000 human single-gene 
disorders, which impose a significant burden on human 
health worldwide. Therefore, the development of nanomed-
icine approaches for treating single-gene disorders based on 
engineered nucleases may have a significant impact to hu-
man health. 
6  Opportunities and challenges in nanomedicine 
Nanomedicine research and development that utilize 
nano-scale (1–100 nm) features of materials and structures 
at atomic, molecular and macromolecular levels have the 
potential to provide fundamental understanding of biologi-
cal processes in living cells that would be otherwise un-
thinkable, establish the ability to precisely measure, control 
and manipulate the functions of biomolecules in vivo, and 
create medical reagents, devices and systems that have nov-
el properties and functions because of their nano-scale fea-
tures. For example, the diagnosis and treatment of athero-
sclerosis represents an area where targeted nanoparticles 
have great potential for noninvasive diagnosis, targeted 
therapy, and plaque stabilization. Specifically, it is possible 
to have nano-scale multifunctional devices that could detect 
thrombotic events in vivo and deliver therapeutic agents 
such as anticoagulants as needed. Therapeutic nanoparticles 
have the potential for curing inflammatory lung diseases, 
including biodegradable nano- and microparticles releasing 
anti-oxidant and anti-inflammatory drug molecules, and 
nanoparticles capable of sensing alveolar function and re-
leasing drugs only when needed, restricting drug delivery to 
affected areas in heterogeneous disease conditions. Nano-
medicine approaches may enable early detection of cancer, 
and the targeted delivery of anti-cancer drugs into tumor 
tissue, dramatically increasing their efficacy and decreasing 
the side effects. Nanoparticle (NP) based imaging probes 
may enable us to detect cancer stem cells and reveal the 
interaction between normal and cancer cells during the ear-
liest stages of the cancer development, thus having the po-
tential to eliminate death and suffering from cancer.  
To successfully develop nanomedicine as a new field, 
there are significant challenges in achieving high efficacy 
and safety, and in technology translation and commerciali-
zation. Some of the major challenges in these areas are 
summarized in Table 2. Clearly, for nanomedicine to gener-
ate a large clinical impact, it has to produce methods, de-
vices, drugs, procedures, tools or reagents that are better 
than existing counterparts, such as simpler, faster, cheaper 
or safer; more sensitive, specific or robust; or having en-
tirely new functionalities. Achieving these will require con-
certed efforts by researchers in nano-science, nano-    
engineering, biology, chemistry, medicine as well as experts 
in manufacturing, commercialization, regulation, safety, and 
environmental protection.  
To effectively develop nanomedicine, we must take a 
systems approach in addressing the major challenges. For 
example, for nanoparticles as an in vivo imaging contrast 
agent, the size and surface chemistry of nanoparticles need 
to be tailored to achieve optimal sensitivity, signal-to-noise, 
biodistribution, and the amount required in a well-balanced 
fashion. Similarly, for nanoparticle-based in vivo drug/gene 
delivery, the nano-carriers need to be well designed to 
achieve adequate cargo loading, controlled release, specific 
organ/cell internalization and accumulation, and quick 
clearance/degradation of the nanoparticles. For disease 
treatment using engineered nucleases, it is necessary to op-
timize the design of ZFNs or TALENs so that both high 
gene correction efficiency and minimal off-target effect can 
be realized. Most of the nanomedicine approaches involve 
cellular and/or in vivo delivery of nanoparticles, proteins, 
Table 2  Major challenges in nanomedicine 
Efficacy Safety Translation Commercialization 
Quality of NP synthesis & functional-
ization 
Sensitivity & specificity 
Signal-to-noise 
Tunable blood circulation half-life 
Optimal biodistribution 
Efficiency & throughput 
Controllability & tunability 








Impact to medicine 
Imaging probes & contrast agents 
Targeted delivery vehicles  
Molecular devices 
NP based drugs 






Barriers in regulation 
Robustness 
Cost 
Stability & storage life 
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DNA/RNA or drug molecules, which is a common chal-
lenge, therefore requires a systematical study. To commer-
cialize nanotechnologies for medical applications, new FDA 
policies, regulations and guidelines are being developed in 
the US, China and the rest of the world. 
Despite the significant challenges and regulatory barriers 
in developing nanomedicine and its commercialization, 
huge progress has been made in nanomedicine over the last 
ten years and many nanotechnology-related clinical trials 
have been, or are being, conducted. Many commercial 
products based on nanomedicine approaches have emerged, 
and will continue to emerge, which may significantly im-
pact on all areas of medicine. Nanomedicine will dramati-
cally exceed what has occurred to date in the history of 
medicine, and will likely revolutionize medicine. 
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